SAB Biotherapeutics, Inc. SABS NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score

56/100

2/6 Pass

SharesGrow Intrinsic Value

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

SAB Biotherapeutics, Inc. (SABS) trades at a trailing P/E of 5.4. Trailing earnings yield is 18.35%. Graham Number is $11.01.

Criteria proven by this page:

VALUE (100/100, Pass) — P/E is below market average (5.4); analyst target implies upside (+81.3%); earnings yield beats bond yields (18.35%).
Trailing Earnings Yield 18.35% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income.
Analyst consensus target $7.00 (+81.3% upside) — significant upside potential according to Wall Street analysts.

Overall SharesGrow Score: 54/100 with 2/7 criteria passed.

SharesGrow 7-Criteria Score

56/100

SG Score

View full scorecard →

✓

VALUE

100/100

Price-to-Earnings & upside

Proven by this page

✓

FUTURE

94/100

Analyst consensus

→ Forecast

✗

PAST

25/100

→ Income

HEALTH

67/100

Debt-to-Equity & liquidity

→ Health

✗

MOAT

0/100

→ Income

GROWTH

48/100

→ Income

—

INCOME

N/A

No coverage

Valuation Snapshot — SABS

Valuation Multiples

P/E (TTM)5.4

Forward P/EN/A

PEG RatioN/A

Forward PEGN/A

P/B Ratio0.48

P/S Ratio0.00

EV/EBITDA1.9

Per Share Data

EPS (TTM)$0.69

Book Value / Share$7.84

Revenue / Share$0.00

FCF / Share$-2.37

Yields & Fair Value

Earnings Yield18.35%

Dividend Yield0.00%

Graham Number$11.01

SharesGrow IV$5.59 (+44.8%)

Analyst Target$7.00 (+81.3%)

Historical Valuation

Year	P/E (TTM)	PEG Ratio	P/B Ratio	P/S Ratio	Dividend Yield
2019	-49.1	0.00	-191.37	128.19	-
2020	21.9	-0.01	11.31	7.99	-
2021	-19.8	0.11	8.81	5.58	-
2022	-1.4	-0.15	0.83	1.07	-
2023	-0.9	-0.01	0.66	16.96	-
2024	-1.0	0.02	1.35	26.54	-
2025	5.4	-0.05	0.48	0.00	-

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2019	$-0.22	$3.44M	$-8.99M	-261.1%
2020	$7.45	$55.24M	$20.12M	36.4%
2021	$-6.30	$60.88M	$-17.15M	-28.2%
2022	$-4.31	$23.9M	$-18.74M	-78.4%
2023	$-7.64	$2.24M	$-42.19M	-1884.5%
2024	$-3.68	$1.32M	$-34.11M	-2579.8%
2025	$-0.79	$0.00	$13.27M	-

Analyst Estimates

Year	EPS (Avg)	EPS Range	Revenue (Avg)	Revenue Range	Analysts
2026	$-0.73	$-1.35 – $-0.30	$333.33K	$333.33K – $333.33K	3
2027	$-0.45	$-0.50 – $-0.43	$83.33K	$83.33K – $83.33K	3
2028	$-0.47	$-0.92 – $-0.29	$11.87M	$11.87M – $11.87M	6
2029	$-0.37	$-0.37 – $-0.37	$83.38M	$83.38M – $83.38M	4
2030	$-0.03	$-0.03 – $-0.03	$218.48M	$218.48M – $218.48M	2